Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb

The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested